Lower Prices and More Transparency — What Consumers Want from Drug Companies But Aren’t Getting

Prices and transparency – two topics that you will never hear drug companies actively talk about. Continue reading

Comments are closed.

Remember this Number

56. Remember it next time you hear Gilead or a defender of its pricing say that the price of Sovaldi is a reflection of the cost of discovery. Continue reading

As House Committee Talks MA, AHIP Highlights Benefits, Challenges Ahead

This morning, a powerful House panel held a hearing on Medicare Advantage (MA), in part to examine the impact that further cuts to the program would have on American seniors. In advance of the hearing, America’s Health Insurance Plans (AHIP) submitted testimony to the Ways and Means Committee highlighting the importance of MA and laying out recommendations to preserve the care and high satisfaction that seniors have with the program. Continue reading